Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
7(70%)
Results Posted
0%(0 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
1
10%
Ph not_applicable
4
40%
Ph phase_1
4
40%
Ph phase_3
1
10%

Phase Distribution

4

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
4(40.0%)
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
1(10.0%)
N/ANon-phased studies
4(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

7

trials recruiting

Total Trials

10

all time

Status Distribution
Active(7)
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Recruiting5
Active, not recruiting2
Completed1
Terminated1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
7
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (40.0%)
Phase 21 (10.0%)
Phase 31 (10.0%)
N/A4 (40.0%)

Trials by Status

recruiting550%
completed110%
active_not_recruiting220%
terminated110%
suspended110%

Recent Activity

Clinical Trials (10)

Showing 10 of 10 trials
NCT07012044Phase 1

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Recruiting
NCT04539366Phase 1

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

Suspended
NCT06997068Phase 2

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Recruiting
NCT06811116Phase 1

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

Recruiting
NCT05019716Phase 1

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Recruiting
NCT03699995Not Applicable

MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma

Terminated
NCT04095364Phase 3

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active Not Recruiting
NCT06037863Not Applicable

Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial

Active Not Recruiting
NCT04498221Not Applicable

Lymphatic Mapping Of Oropharyngeal Cancer

Recruiting
NCT00925366Not Applicable

Which is the Most Reliable Radiologic Examination for the Diagnosis of Rotator Cuff Tendon Tear?

Completed

All 10 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
10